Cologne, Germany

Christoph Gerdes

This inventor holds 31 USPTO granted patents and 24 published patent applications, plus 1 CIPO patent and 15 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft, Bayer Intellectual Property Gmbh. Active years: 1997-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christoph Gerdes. Retrieved from https://idiyas.com/inventor/christoph-gerdes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 31 

% Patents Active = 38.7

 

 

Average Co-Inventor Count = 12.0

ph-index = 6

Forward Citations = 132(Granted Patents)


Location History:

  • Leverkusen, DE (1997 - 2012)
  • Köln, DE (2011 - 2019)
  • Cologne, DE (2021 - 2024)

Company Filing History:


Years Active: 1997-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Substituted S-Alaninate Derivatives
Antibodies
Coagulation Factor XIa
Oxopyridine Derivatives
Cardiovascular Disorders
Piperidines
Integrin Antagonists
Oxazolidinones
Benzodiazepinone Derivatives
Phenylcyclohexylcarboxamides
Multiheterocyclic Pharmaceuticals
Indole Derivatives
31 patents (USPTO):Explore Patents

Title: Christoph Gerdes: Pioneering Innovation in Köln

Introduction:

Christoph Gerdes is a visionary inventor based in Köln, DE, who continues to inspire the next generation of inventors with his dedication to creating a better future through innovation. With an impressive portfolio of 31 patents, Gerdes is a trailblazer in the field of medical advancements and therapeutic solutions.

Latest Patents:

Among his latest patents are groundbreaking inventions such as Substituted S-alaninate derivatives, which are utilized in the treatment and prophylaxis of vascular disorders, particularly thrombotic or thromboembolic complications. Additionally, his invention of Antibodies capable of binding to the coagulation Factor XIa showcases his expertise in developing agents that inhibit platelet aggregation and prevent thrombus formation.

Career Highlights:

Gerdes has made significant contributions to renowned companies such as Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. Through his innovative work, he has fueled advancements in the pharmaceutical industry and has set new standards for medical research and development.

Collaborations:

Throughout his career, Gerdes has collaborated with esteemed professionals in the field, including Anja Buchmüller and Susanne Röhrig. These collaborations have led to the creation of cutting-edge solutions that have a profound impact on the medical community and beyond.

Conclusion:

In conclusion, Christoph Gerdes stands as a beacon of innovation, leading the way in creating transformative solutions for complex medical challenges. His visionary approach and unwavering dedication serve as an inspiration for aspiring inventors worldwide, shaping the future of healthcare and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…